COGT
Cogent Biosciences, Inc.
+0.67 (+2.06%)33.21USD360K成交股數5.8B市值–本益比(近四季)732.1股價營收比–營收年增(近四季)2026-11-03下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | – | – | – | – | – | – | – | – | – | – | – | – |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 70.8M | 75.4M | 75.6M | 69.0M | 62.2M | 63.0M | 63.6M | 54.3M | 52.7M | 48.7M | 50.1M | 38.9M |
| 銷售管理費用 | 31.8M | 28.2M | 23.9M | 14.4M | 13.4M | 11.9M | 11.8M | 10.1M | 9.7M | 9.5M | 9.5M | 8.2M |
| 營業利益 | −103M+36% | −104M+38% | −99.5M+32% | −83.4M+29% | −75.6M+21% | −74.9M+29% | −75.4M+27% | −64.4M+37% | −62.4M | −58.2M | −59.6M | −47.1M |
| 營業利益率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 稅後淨利 | −96.4M+31% | −97.4M+35% | −102M+45% | −80.9M+37% | −73.5M+26% | −72.0M+32% | −70.6M+28% | −59.0M+34% | −58.3M | −54.4M | −55.4M | −44.1M |
| 淨利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 稀釋 EPS | -0.52-2% | -0.53+2% | -0.61+17% | -0.50+16% | -0.53+8% | -0.52+225% | -0.52-19% | -0.43-27% | -0.49 | -0.16 | -0.64 | -0.59 |
| 稀釋股數 | 171M | 162M | 129M | 138M | 114M | 113M | 110M | 99.2M | 94.8M | 79.7M | 86.2M | 74.8M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 181M | 241M | 312M | 125M | 128M | 126M | 97.0M | 88.2M | 216M | 53.2M | 86.8M | 214M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 835M | 903M | 938M | 426M | 275M | 284M | 384M | 430M | 476M | 313M | 355M | 392M |
| 有息負債 | 223M | 223M | 223M | 44.3M | 43.9M | – | – | – | – | – | – | – |
| 總負債 | 302M | 295M | 301M | 123M | 120M | 64.8M | 69.4M | 56.7M | 53.8M | 55.6M | 52.5M | 43.9M |
| 股東權益 | 532M | 608M | 636M | 302M | 155M | 219M | 315M | 373M | 422M | 258M | 303M | 348M |
| 負債比 | 36.2% | 32.7% | 32.1% | 29.0% | 43.6% | 22.8% | 18.1% | 13.2% | 11.3% | 17.7% | 14.8% | 11.2% |
| 淨現金(現金 − 有息負債) | −42.3M | 18.0M | 89.1M | 81.0M | 83.6M | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −86.9M+31% | – | – | – | −66.5M | – | – | −52.5M | – | – | – |
| 資本支出 | – | 449K | – | – | – | 547K | – | – | 70K | – | – | – |
| 自由現金流 | – | −87.3M+30% | – | – | – | −67.1M | – | – | −52.6M | – | – | – |
| 折舊攤銷 | – | 626K | – | – | – | 640K | – | – | 599K | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | – | – | −329M | –% | -2.16 | −266M |
| FY2024 | – | – | −256M | –% | -1.94 | −208M |
| FY2023 | – | – | −192M | –% | -1.94 | −156M |
| FY2022 | – | – | −140M | –% | -1.73 | −126M |
| FY2021 | – | – | −72.3M | –% | -1.87 | −60.5M |
| FY2020 | 7.9M | -65.0% | −74.8M | -950.4% | -16.17 | – |
| FY2019 | 22.5M | +131.1% | −31.8M | -141.5% | -4.18 | −41.5M |
| FY2018 | 9.7M | – | −34.5M | -354.8% | -1.39 | −33.0M |